Abstract Details

Title Evaluation of Combination Therapy (Sumatriptan/Naproxen Sodium) Versus Monotherapy for the Acute Treatment of Migraine Using a Novel Clinical Endpoint: Sustained Pain Free and No Adverse Events

Topic Headache/Other Pain Syndromes

Presentation(s) (-)

Poster/Presentation
Number 035

Objective

Background

Design/Methods

Results

Conclusions

Authors/Disclosures
Stephen H. Landy, MD, FAAN	Dr. Landy has received personal compensation in the range of $100,000-$499,999 for serving on a Speakers Bureau for Allergan/Abbvie, Amgen, Biohaven, Lilly, Lundbeck, Teva.
	No disclosure on file
Michelle Lener, PharmD (GlaxoSmithKline)	No disclosure on file
Susan A. McDonald, MA (GlaxoSmithKline)	No disclosure on file
	No disclosure on file
	No disclosure on file

��ɫ��

��ɫ��

Abstract Details

��ɫ����

��ɫ����

��ɫ��

��ɫ��